Related Experiment Videos
Platelet-activating factor antagonism improves ventricular contractility in endotoxemia
M J Herbertson1, H A Werner, K R Walley
1Pulmonary Research Laboratory, University of British Columbia, Vancouver, Canada.
Critical Care Medicine
|February 1, 1997
Summary
Platelet-activating factor plays a modest role in sepsis-induced decreases in left ventricular contractility. Inhibiting this factor may improve cardiac function and hemodynamics during sepsis.
Area of Science:
- Cardiovascular Physiology
- Sepsis Pathophysiology
- Pharmacology
Background:
- Endotoxins trigger platelet-activating factor (PAF) production, leading to decreased myocardial contractility in sepsis models.
- PAF itself impairs left ventricular contractility.
Purpose of the Study:
- To investigate the contribution of PAF to the reduction in left ventricular contractility observed during sepsis.
Main Methods:
- A prospective, randomized, controlled animal study was conducted using 22 juvenile pigs.
- Pigs received either a PAF receptor antagonist (L-659,989) or vehicle before endotoxin or saline administration.
- Left ventricular contractility was assessed by measuring maximum elastance (Emax) via pressure-volume relationships.
Main Results:
- Endotoxin administration decreased Emax by 41% and mean arterial pressure by 32% in control pigs.
- In pigs pretreated with L-659,989, the decreases in Emax (26%) and mean arterial pressure (16%) were significantly attenuated.
- These findings indicate a statistically significant protective effect of the PAF antagonist.
Conclusions:
- Platelet-activating factor plays a significant, albeit modest, role in the early decline of left ventricular contractility following endotoxin exposure.
- Inhibiting PAF during sepsis could offer therapeutic benefits for preserving cardiac mechanics and hemodynamics.